Berberine dosage and evidence

Overview

Mechanism of action

An isoquinoline alkaloid that activates AMP-activated protein kinase, which is the same node metformin acts through, largely via mild inhibition of mitochondrial complex I raising the AMP to ATP ratio. Downstream that increases glucose uptake, suppresses hepatic gluconeogenesis and reduces lipogenesis. It also upregulates LDL receptor expression by a route independent of statins, which explains the lipid effects, and alters gut microbiota composition. Oral bioavailability is very low, under 1%, so much of the effect is likely mediated in the gut and by metabolites rather than by systemic berberine.

Human evidence

The largest randomised base of any metabolic supplement on this site, with consistent direction and clinically meaningful effect sizes, and no clinical outcome data at all.

• 46 randomised trials pooled: HbA1c down 0.73 percentage points, which is in the range expected of a low-dose oral diabetes drug.
• Against metformin directly, in 36 newly diagnosed patients over three months, glucose lowering was similar.
• A 116 person randomised trial in type 2 diabetes with dyslipidaemia: HbA1c 7.5% to 6.6% and LDL 3.23 to 2.55 mmol/L at 1.0 g/day for three months.
• A 34 person prediabetes pilot of a branded berberine moved fasting glucose from 6.75 to 5.33 mmol/L over 12 weeks.
• Insulin resistance measures improved, with HOMA-IR down 0.71 and fasting insulin down substantially.
• Lipids improved across the same pooled analysis, with triglycerides, total cholesterol and LDL all reduced and HDL raised.
• Tolerability is the main practical limit: 34.5% of patients in the metformin comparison had transient gastrointestinal effects, which is why dosing is split across meals.
• No trial has measured cardiovascular events, progression to complications, or mortality.

What this does not tell you: Most trials are small, many are from one region, and trial quality across the pooled set is mixed, which the reviewers acknowledge. Several commercial products test berberine in combination with other agents, so those results cannot be attributed to berberine. The absence of outcome data matters more here than for most supplements, because berberine is being used as a substitute for a drug class that does have outcome data. Metformin has been tested against clinical endpoints for decades; berberine has not been tested against them at all.

Reading the research record

The evidence, charted

Key studies & citations

• Human2008
  Efficacy of berberine in patients with type 2 diabetes mellitus

  Berberine lowered blood sugar about as well as metformin in a very small, short study. Thirty-six adults newly diagnosed with type 2 diabetes took either berberine or metformin three times a day for three months. Average blood sugar over three months fell from 9.5 to 7.5 percent on berberine. A second group of 48 poorly controlled patients added berberine and fell from 8.1 to 7.3 percent. About a third had stomach upset that passed. Thirty-six people cannot settle a question about a lifelong disease.

  The head to head everyone cites. 36 adults with newly diagnosed type 2 diabetes randomised to berberine or metformin 0.5 g three times daily for three months, with the hypoglycaemic effect similar between them. HbA1c fell from 9.5% to 7.5% on berberine. A second arm added berberine in 48 poorly controlled patients, with HbA1c falling from 8.1% to 7.3%. 34.5% of patients had transient gastrointestinal adverse effects.

  PMID 18442638 Metabolism
• Review2021
  The effect of berberine on metabolic profiles in type 2 diabetic patients: a systematic review and meta-analysis of randomized controlled trials

  46 randomised trials. HbA1c mean difference minus 0.73 (95% CI minus 0.97 to minus 0.51), fasting glucose minus 0.86 mmol/L, two-hour postprandial glucose minus 1.26 mmol/L, HOMA-IR minus 0.71 and BMI minus 1.07. Lipids improved as well. The authors describe strong evidence for efficacy, particularly as an add-on therapy.

  PMID 34956436 Oxidative Medicine and Cellular Longevity
• Review2019
  Metabolic effect of berberine-silymarin association: a meta-analysis of randomized, double-blind, placebo-controlled clinical trials

  A separate pooled analysis of berberine combined with silymarin, included here because it illustrates the formulation problem: much of the commercial literature tests combinations, and a combination result cannot be attributed to berberine alone.

  PMID 30632209 Phytotherapy Research
• Human2008
  Treatment of type 2 diabetes and dyslipidemia with the natural plant alkaloid berberine

  A larger diabetes trial than the famous 36 person head to head. 116 adults with type 2 diabetes and high lipids took 1 gram of berberine a day, or a dummy, for three months. Fasting sugar fell from 7.0 to 5.6. HbA1c fell from 7.5 to 6.6 percent. Triglycerides, total cholesterol and LDL fell too. This is still a biomarker trial, not an event trial.

  116 adults with type 2 diabetes and dyslipidaemia randomised to berberine 1.0 g/day or placebo for 3 months. Fasting glucose 7.0 to 5.6 mmol/L, post-load 12.0 to 8.9, HbA1c 7.5% to 6.6%, triglycerides 2.51 to 1.61, LDL 3.23 to 2.55, all versus placebo p <= 0.001.

  PMID 18397984 Journal of Clinical Endocrinology and Metabolism
• Human2023
  Efficacy and safety of HIMABERB berberine on glycemic control in patients with prediabetes: double-blind, placebo-controlled, and randomized pilot trial

  A small prediabetes pilot moved the same sugar numbers. 34 people took a branded berberine, or a dummy, for 12 weeks. Fasting sugar fell from 6.75 to 5.33. The two hour sugar test fell too. 34 people is a pilot. A branded product result does not transfer to every bottle on the shelf.

  34 adults with prediabetes randomised to HIMABERB berberine or placebo for 12 weeks. Fasting glucose 6.75 to 5.33 mmol/L, two-hour OGTT 10.44 to 8.12, with parallel falls in fasting insulin and HbA1c versus control.

  PMID 37679692 BMC Endocrine Disorders

What users report

Self-reported experiences, not evidence. Nothing below was measured under controlled conditions, and reports like these cannot separate a real effect from placebo, from the training or diet change that accompanied it, or from what the product actually contained. They are here because knowing what people describe, including what goes wrong, is worth reading alongside the studies.

• Framed throughout as a metformin-like glucose lowering supplement, and the comparison with metformin is made in almost every thread, including the suggestion that it may interfere with B12 absorption in the same way.
• Amounts described are in the hundreds of milligrams two or three times daily with meals, and poor absorption is the standing explanation offered for why results vary so widely between people.
• The side effects described are gastrointestinal: upset stomach, nausea and constipation, with rash and headache less often. Constipation is the one raised most.
• A specific caution that recurs is that combining it with fasting or a low carbohydrate diet can drive blood sugar lower than either does alone, described as an additive effect to plan around rather than as a rare accident.
• Interaction risk through CYP enzymes is raised repeatedly, particularly alongside statins, and rare arrhythmia and QT concerns are mentioned, though as literature rather than as anyone's experience.
• It usually appears as one component of a longevity stack rather than alone, including alongside rapamycin, which means most accounts of how someone felt on it cannot separate it from everything else they were taking.

Sources: Supplements and Medicine and Diseases threads on LongeCity covering berberine downsides, berberine with fasting, and berberine appearing inside rapamycin stacks, found by site-restricted search, September 2026. Nothing above is attributed to any specific post and no post is reproduced.